Skip to main content

Advertisement

SpringerLink
Log in

Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer diagnosis

  • Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

Prostate cancer (PCa) is one of the most common malignancies in men and one of the leading causes of cancer-related deaths; circulating tumor cells (CTC) are malignant cells that have broken off from original tumor or metastatic sites and extravasated into the blood vessels either naturally or maybe as a consequence of surgical procedures. This study aims to explore the feasibility of liquid biopsy technique to diagnose prostate cancer.

Method

We constructed an assay platform integrating magnetic separation and fluorescence in situ hybridization (FISH) to effectively capture prostate cancer CTCs and evaluate the distribution between healthy volunteers and prostate cancer patients, respectively.

Results

There was a significant difference in the number of CTCs between the healthy population and prostate cancer patients (P < 0.001). The results of the study showed that the CTCs capture identification system has good sensitivity and specificity in identifying prostate cancer patients.

Conclusion

The CTCs test allows us to accurately identify patients who are at high risk for prostate cancer, allowing for early intervention and treating patients effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  • Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M (2014) Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci USA 111(9):3514–3519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alix-Panabières C, Pantel K (2014) Challenges in circulating tumour cell research. Nat Rev Cancer 14(9):623–631

    Article  PubMed  Google Scholar 

  • Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AGJ, Uhr JW, Terstappen LWMM (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10(20):6897–6904

    Article  PubMed  Google Scholar 

  • Antonarakis ES et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038

    Article  PubMed  PubMed Central  Google Scholar 

  • Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179(6):2187–2191

    Article  PubMed  Google Scholar 

  • Eisenwort G, Jurkin J, Yasmin N, Bauer T, Gesslbauer B, Strobl H (2011) Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-β1-dependent human epidermal Langerhans cells. J Invest Dermatol 131(10):2049–2057

    Article  CAS  PubMed  Google Scholar 

  • Gao Y et al (2016) Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization. J Exp Clin Cancer Res 35:66

    Article  PubMed  PubMed Central  Google Scholar 

  • Habermann JK, Doering J, Hautaniemi S, Roblick UJ, Bündgen NK, Nicorici D, Kronenwett U, Rathnagiriswaran S, Mettu RKR, Ma Y, Krüger S, Bruch HP, Auer G, Guo NL, Ried T (2009) The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int J Cancer 124(7):1552–1564

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Han Y, Luo Y, Wang Y, Chen Y, Li M, Jiang Y (2016) Hepatocyte growth factor increases the invasive potential of PC-3 human prostate cancer cells via an ERK/MAPK and Zeb-1 signaling pathway. Oncol Lett 11(1):753–759

    Article  CAS  PubMed  Google Scholar 

  • Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FKH, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H (2009) Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with cell search assay and association with bone metastases and with survival. Clin Chem 55(4):765–773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hristozova T et al (2011) The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol 22:1878–1885

    Article  CAS  PubMed  Google Scholar 

  • Huang XY, Li F, Li TT, Zhang JT, Shi XJ, Huang XY, Zhou J, Tang ZY, Huang ZL (2023) A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma. J Nanobiotechnology 21(1):25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kiciński M, Vangronsveld J, Nawrot TS (2011) An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One 6(10):e27130

    Article  PubMed  PubMed Central  Google Scholar 

  • Kops GJPL, Weaver BAA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5(10):773–785

    Article  CAS  PubMed  Google Scholar 

  • Lee AJX, Endesfelder D, Rowan AJ, Walther A, Birkbak NJ, Futreal PA, Downward J, Szallasi Z, Tomlinson IPM, Howell M, Kschischo M, Swanton C (2011) Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 71(5):1858–1870

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lin PP (2015) Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells. Clin Transl Med 4:38

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu Y, Li Q, Chen T, Shen T, Zhang X, Song P, Liu L, Liu J, Jiang T, Liang X (2021) Clinical verification of vimentin/EpCAM immunolipid magnetic sorting system in monitoring CTCs in arterial and venous blood of advanced tumor. J Nanobiotechnology 19(1):185

  • Liu C et al (2021) The value of circulating tumor cells with positive centromere probe 8 in the diagnosis of small pulmonary nodules. Transl Oncol 14:101052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C (2014) Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate Int 2(3):133–139

    Article  PubMed  PubMed Central  Google Scholar 

  • Lu X et al (2021) Evaluation of a new magnetic bead as an integrated platform for systematic CTC recognition, capture and clinical analysis. Colloids Surf B Biointerfaces 199:111542

    Article  CAS  PubMed  Google Scholar 

  • McDaniel AS, Ferraldeschi R, Krupa R, Landers M, Graf R, Louw J, Jendrisak A, Bales N, Marrinucci D, Zafeiriou Z, Flohr P, Sideris S, Crespo M, Figueiredo I, Mateo J, de Bono JS, Dittamore R, Tomlins SA, Attard G (2017) Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. BJU Int 120(5B):E30-44

    Article  CAS  PubMed  Google Scholar 

  • McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C (2012) Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 13(6):528–538

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2(11):995–1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • O’Rourke ME (2011) The prostate-specific antigen screening conundrum: examining the evidence. Semin Oncol Nurs 27(4):251–259

    Article  PubMed  Google Scholar 

  • Passerini V, Ozeri-Galai E, de Pagter MS, Donnelly N, Schmalbrock S, Kloosterman WP, Kerem B, Storchová Z (2016) The presence of extra chromosomes leads to genomic instability. Nat Commun 7:10754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pisapia P, Malapelle U, Troncone G (2019) Liquid biopsy and lung cancer. Acta Cytol 63:489–496

    Article  CAS  PubMed  Google Scholar 

  • Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273(7):548–552

    Article  CAS  PubMed  Google Scholar 

  • Saini S (2016) PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol (Dordr) 39(2):97–106

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Morris MJ, Larson S, Heller G (2013) Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol 10(4):225–234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R (2016) Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441–1449

    Article  PubMed  PubMed Central  Google Scholar 

  • Sharma S, Zapatero-Rodríguez J, O’Kennedy R (2017) Prostate cancer diagnostics: clinical challenges and the ongoing need for disruptive and effective diagnostic tools. Biotechnol Adv 35(2):135–149

    Article  PubMed  Google Scholar 

  • Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, Ilyas A, Asghar W (2018) Circulating tumor cell isolation, culture, and downstream molecular analysis. Biotechnol Adv 36(4):1063–1078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24(18):1967–2000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shetye JD, Liljefors ML, Emdin SO, Frödin JE, Strigård K, Mellstedt HT, Porwit A (2004) Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients. Anticancer Res 24(4):2375–2383

    PubMed  Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224

    Article  CAS  PubMed  Google Scholar 

  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108

    Article  PubMed  Google Scholar 

  • Toss A, Mu Z, Fernandez S, Cristofanilli M (2014) CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med 2:108

    PubMed  PubMed Central  Google Scholar 

  • Wicha MS, Hayes DF (2011) Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 29:1508–1511

    Article  PubMed  Google Scholar 

  • Yang Z, Bai H, Hu L, Kong D, Li G, Zhao C, Feng L, Cheng S, Shou J, Zhang W, Zhang K (2022) Improving the diagnosis of prostate cancer by telomerase-positive circulating tumor cells: a prospective pilot study. EClinicalMedicine 43:101161

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Author notes

  1. Junyong Chen, Tao Xie and Jing Yang have contributed equally to this work.

Authors and Affiliations

  1. Department of Urology, Zhuhai People’s Hospital (Zhuhai Hospital Affiliated with Jinan University), 79 Kangning Rd., Zhuhai, 519000, China

    Junyong Chen, Tao Xie, Xuehua Lin, Long Huang, Shiya Su & Jian Deng

  2. Department of Pathology, Zhuhai People’s Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, 519000, China

    Jing Yang

Authors
  1. Junyong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tao Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuehua Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Long Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shiya Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JC, TX and JY wrote the manuscript, XL collected and analyzed the data, LH and SS were in charge of the methodology and conception, JD administrated the work. All authors reviewed and approved the submitted version of the manuscript.

Corresponding authors

Correspondence to Long Huang, Shiya Su or Jian Deng.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, J., Xie, T., Yang, J. et al. Feasibility study of expressing epcam + /vimentin + CTC in prostate cancer diagnosis. J Cancer Res Clin Oncol 149, 8699–8709 (2023). https://doi.org/10.1007/s00432-023-04819-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-04819-7

Keywords

Search

Navigation